Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development
You may also be interested in...
Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?
Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?
BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere
BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.
BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere
BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.